Representatives from the pharmaceutical and health insurance industries debated the potential outcomes of drug-pricing proposals Oct. 30 at the Milken Future of Health Summit in Washington, D.C., according to STAT.

The Nevada Board of Pharmacy has failed to conduct mandatory background checks of drug wholesalers since 2007, an investigation found, according to the Las Vegas Review-Journal.

The White House has indicated it will endorse a more modest bill than House Speaker Nancy Pelosi's drug-pricing plan, according to The Hill.

Amgen is investing $2.7 billion in a Chinese drugmaker, BeiGene, giving it a 20.5 percent stake in the company, according to CNBC.

Amgen is ending most of its neuroscience research, which will result in 180 employees losing their jobs, according to EndPoints News. 

Below are 10 of the top pharmacy stories published by Becker's Hospital Review in October, beginning with the most popular:

Biogen and Alkermes won approval Oct. 30 for their new multiple sclerosis drug, Vumerity, according to The Boston Globe.

Walgreens and CareSource, Ohio's largest Medicaid provider, are no longer working together, leaving half of Ohio's Medicaid recipients without access to Walgreens pharmacies, according to The Columbus Dispatch. Walgreens is Ohio's second-largest pharmacy retailer, which means parts of Ohio could…

Walgreens' decision to close its wholly-owned health clinics could serve as a warning to other retailers looking to start their own clinics, according to The Motley Fool. 

Michigan's Senate voted Oct. 30 to reject a state regulatory commission's recommendation to regulate and limit the number of hospitals that can administer CAR-T cell therapy, according to Crain's Detroit Business.